Navigation Links
Pill Reduces Relapses in MS Patients
Date:4/15/2008

First oral drug could benefit many with the autoimmune disease, researchers say

TUESDAY, April 15 (HealthDay News) -- The first pill designed to reduce the number of attacks in people with multiple sclerosis appears to be effective in early tests, Italian researchers report.

The pill was effective in preventing relapses in more than 60 percent of patients who took the pill for three years, according to research that was expected to be presented April 15 the American Academy of Neurology annual meeting, in Chicago.

"All of the current treatments for MS must be injected, so having a pill you can swallow with a glass of water would be a welcome improvement for many people," lead researcher Dr. Giancarlo Comi, from Vita-Salute San Raffaele University in Milan, said in a prepared statement.

In the study, Comi's team treated 281 people with relapsing MS with FTY720 (fingolimod) or a placebo. After six months, two-thirds of the patients who received FTY720 had more than 50 percent fewer relapses, compared with those receiving placebo.

During the three years of the trial, more than 67 percent of the 173 people receiving FTY720 were free of relapses. In addition, 89 percent of the patients were free of disease activity and 75 percent did not develop new lesions or see their lesions enlarge. This was confirmed by MRI scans, the researchers stated.

"The first-line treatments for MS, beta interferon and glatiramer acetate, reduce the relapse rate by only about 30 percent, so this is a significant development for people with MS," Comi said in a statement.

The most commonly reported side effects of FTY720 were headache, flu and cold symptoms.

The drug works by binding to receptors on immune cells, isolating them in the lymph nodes, thereby reducing their ability to cause the damage associated with MS symptoms.

The study was paid for by Novartis Pharma AG, maker of FTY720.

One expert thinks this preliminary data is encouraging, but a lot more needs to be done to prove the drug's effectiveness.

"This is a new drug that has a very strong scientific rationale why it could work," said Dr. John Richert, executive vice president of the National Multiple Sclerosis Society. "Certainly, everything we've seen so far continues to keep us optimistic."

Richert noted that over three years, 77 patients receiving the drug dropped out of the study. "You're left wondering if a more severe adverse event led to the dropouts," he said.

The six-month data where the drug was tested against placebo looks promising, Richert said. "If this turns out to be a safe oral drug that has substantial benefit, that will be very important for many people with MS," he added.

More information

For more on MS, visit the National Multiple Sclerosis Society.



SOURCES: John Richert, M.D., executive vice president, National Multiple Sclerosis Society, New York City; April 15, 2008, presentation, American Academy of Neurology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer by 24 Percent
2. Essential nutrient found in eggs reduces risk of breast cancer by 24 percent
3. Psychological intervention reduces postembolization pain
4. Aspirin Reduces Asthma Risk Among Older Women
5. Low-Fat Dairy Reduces High Blood Pressure Risk
6. HPV vaccine reduces abnormal pap test results
7. Renal Assist Device reduces risk of death from acute kidney failure
8. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
9. Restricting kids video time reduces obesity, randomized trial shows
10. Low-intensity exercise reduces fatigue symptoms by 65 percent, study finds
11. Super Prostate Product - More Beta-sitosterol, all-natural Best Prostate(TM) Formula for Enlarged Prostate and BPH - Increases Urine Flow, Reduces Waking and Improves Quality of Life
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pill Reduces Relapses in MS Patients
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks from ... campaigns regarding the topic of Beauty and Personal Care. , Everyone ... better way to commit to these changes than beginning with personal care and beauty ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... a new 21st century approach to infusing high speed technology into the fabric ... exclusively dedicated to the advancement of healthcare and wellness in a yet-to-be-named, health ...
(Date:1/17/2017)... ... , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , is ... Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror Mirror ... Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as a ...
(Date:1/17/2017)... Metairie, Louisiana (PRWEB) , ... January 17, 2017 ... ... JenCare Senior Medical Center joined the Peoples Health network on Dec. 1, ... Medicare beneficiaries. , “JenCare Senior Medical Center is an exciting addition to our ...
(Date:1/17/2017)... ... ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum casting ... Challenge , the Cradle to Cradle Products Innovation Institute has announced. , ... run through early 2018. The challenges are presented by the Institute in partnership with ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... Phase 3 clinical trial comparing the efficacy and safety ... prevention of hepatic veno-occlusive disease (VOD) in adult and ... are at high risk or at very high risk ... conducted across approximately 100 medical centers in ...
(Date:1/17/2017)... 17, 2017  Market Research Future published a Half Cooked Research ... expected to reach USD 33.6 million during the period 2016 to ... ... Devices Market has been examined as a swiftly growing market and ... demand for endoscopy device in various regions.  The increasing growth in ...
(Date:1/17/2017)... , Jan. 17, 2017 Following ... (SCPC) today praised the Food and Drug Administration,s ... Certain Human Drug Products by Pharmacies and Outsourcing ... a proposed limitation on pre-packaging -- which would ... compliance costs to long term care (LTC) pharmacies.  ...
Breaking Medicine Technology: